On the Horizon - upcoming first generic launches*

TARGET DATE	BRAND NAME	GENERIC NAME	COMMON USE	SALES*
11/26/20	Risperdal Consta	risperidone microspheres	Mental/Neuro disorders	$345
12/6/20	Ofirmev	acetaminophen intravenous	Pain/Inflammation	$379
12/10/20	Saphris	asenapine	Schizophrenia	$255
12/27/20	Absorica	isotretinoin	Acne	$247
1/1/21	Amitiza	lubiprostone	GI Disorders	$456
1/26/21	Zyclara 3.75%	imiquimod	Skin Conditions	$37
2/18/21	Northera	droxidopa	Low Blood Pressure	$333
3/19/21	Impavido	miltefosine	Antiprotozoal Agent	< $10
2Q-2021	Pomalyst	pomalidomide	Cancer	$2,192
4/12/21	Lyrica CR	pregabalin	Neuropathic Pain	< $10
5/29/2021	Zomig Nasal	zolmitriptan	Migraine Headaches	$61
6/22/21	Perforomist	formoterol	Asthma	$291
8/16/21	Sutent	sunitinib	Cancer	$305
9/17/21	Bystolic	nebivolol	High Blood Pressure/Heart Disease	$1,076
11/9/21	Brovana	arformoterol	Asthma	$479
11/11/21	Gilenya 0.25mg	fingolimod	Multiple Sclerosis	$0
12/6/21	Jublia	efinaconazole	Skin Infections	$222
12/20/21	Cayston	aztreonam inhalation	Cystic Fibrosis	$10
4Q-2021	Pradaxa	dabigatran	Anticoagulant	$635
2021	Restasis	cyclosporine ophthalmic	Ophthalmic Conditions	$2,244
2021	Byetta	exenatide	Diabetes	$134
2021	Chantix	varenicline	Smoking Cessation	$1,221

* = Sales in Millions, IMS Sales 2018